Jogendra Singh
Psychiatric/Mental Health · Redlands, CANPI 1174998843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 610 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,385, 3.6 times the $1,205 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 610 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$997
- Alkermes, Inc.$986
- plus $5K from 22 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Brainsway USA Inc$1K
What the payments were for
- Food & beverage$12,969100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 73 | $1,637 |
| Otsuka America Pharmaceutical, Inc. | 70 | $1,560 |
| Neurocrine Biosciences, Inc. | 45 | $1,212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,142 |
| AbbVie | 51 | $997 |
| Alkermes, Inc. | 31 | $986 |
| Johnson & Johnson | 40 | $969 |
| E.r. Squibb & Sons, L.L.C. | 39 | $850 |
| Lundbeck LLC | 38 | $476 |
| Axsome Therapeutics, Inc. | 16 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $363 |
| Corium, LLC | 18 | $345 |
| Bausch Health US, LLC | 13 | $289 |
| Almatica Pharma LLC | 13 | $287 |
| Sunovion Pharmaceuticals Inc. | 26 | $282 |
| Vanda Pharmaceuticals Inc. | 14 | $249 |
| Supernus Pharmaceuticals, Inc. | 12 | $246 |
| Idorsia Pharmaceuticals US Inc | 3 | $180 |
| Tris Pharma Inc | 8 | $178 |
| Indivior Inc. | 10 | $172 |
| Sage Therapeutics, LLC | 3 | $68 |
| Noven Therapeutics, LLC | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Brainsway USA Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,728
- ARISTADA$429
- REXULTI$366
- INVEGA SUSTENNA$364
- INGREZZA$306
- COBENFY$257
- UZEDY$250
- CAPLYTA$130
- Auvelity$125
- VRAYLAR$124
- AUSTEDO$122
- ARISTADA INITIO$107
- SPRAVATO$105
- Dyanavel XR$103
How this compares
$13,001 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 122 | $55,333 |
| VraylarCariprazine Hcl | 35 | $53,042 |
| TrintellixVortioxetine Hydrobromide | 37 | $22,278 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,777 |
| BelsomraSuvorexant | 24 | $10,406 |
| Quetiapine Fumarate | 296 | $6,268 |
| Duloxetine Hcl | 215 | $4,790 |
| Hydroxyzine Hcl | 124 | $3,167 |
| Vilazodone Hcl | 19 | $3,161 |
| Varenicline Tartrate | 11 | $2,553 |
| Bupropion XlBupropion Hcl | 136 | $2,530 |
| Aripiprazole | 146 | $2,376 |
| Ziprasidone Hcl | 16 | $2,290 |
| Trazodone Hcl | 284 | $1,976 |
| Buspirone Hcl | 160 | $1,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $997 | $53,04235 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $363 | $22,27837 claims |
| Alkermes, Inc.Lybalvi | $986 | $16,77711 claims |
| Almatica Pharma LLCSertraline Hcl | $287 | $1,166168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Redlands
- Liberty MaciasRedlands$288K
- John AdenijiRedlands$29K
- Magnus IhemeduRedlands$15K
- Akta PatelRedlands$11K
- Linda JacksonRedlands$11K
- Carey MartinMillbrae$745K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.